Invention Grant
- Patent Title: Selective matrix metalloproteinase inhibitors
-
Application No.: US15961497Application Date: 2018-04-24
-
Publication No.: US10253013B2Publication Date: 2019-04-09
- Inventor: Mayland Chang , Shahriar Mobashery
- Applicant: University of Notre Dame du Lac
- Applicant Address: US IN South Bend
- Assignee: University of Notre Dame du Lac
- Current Assignee: University of Notre Dame du Lac
- Current Assignee Address: US IN South Bend
- Agency: Haukaas Fortius PLLC
- Agent Michael H. Haukaas
- Main IPC: C07D331/02
- IPC: C07D331/02 ; C07D303/34 ; C07D413/12 ; A61K9/00 ; A61K31/38 ; A61K31/4245

Abstract:
The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The compounds can be selective MMP inhibitors, for example, selective inhibitors of MMP-2, MMP-9, and/or MMP-14. The disease, disorder, or condition can include, for example, stroke, neurological disorders, ophthalmological disorders, or wounds, such as chronic wounds or diabetic wounds.
Public/Granted literature
- US20180237412A1 SELECTIVE MATRIX METALLOPROTEINASE INHIBITORS Public/Granted day:2018-08-23
Information query